VIDEO: Extension study shows long-term efficacy, safety of faricimab in DME
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Arshad M. Khanani, MD, MA, FASRS, discusses the just-released 4-year efficacy and safety outcomes of faricimab in diabetic macular edema.
Khanani said the RHONE-X extension study found that patients maintained the vision and central subfield thickness improvements seen in the YOSEMITE and RHINE trials, and absence of DME was achieved in more than 90% of patients by the end of the study. In addition, faricimab was well tolerated through years 3 and 4 of RHONE-X.
“I think this dataset is very relevant for clinicians,” he said. “Where YOSEMITE and RHINE data showed us that starting patients with dual inhibition with faricimab is helpful in terms of disease control and in terms of drying, this data builds on that and also shows that switching patients from aflibercept to faricimab will improve the status of DME control.”
Collapse
Khanani A. Four-year outcomes of faricimab in DME: First time safety and efficacy results from the RHONE-X long-term extension trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts